Basi Ali, Sohrabkhani Shahab, Zamani Farhad, Baghai-Wadji Masoud, Rabiei Neda, Razavi Seyyed-Mohsen, Ajdarkosh Hossein
Assistant professor of Medical Oncology and Hematology, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Internist, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Int J Hematol Oncol Stem Cell Res. 2013;7(4):24-8.
Recent researches have led to find strategies to prevent relapse and to improve survival for gastric cancer patients, including preoperative neo-adjuvant approaches. However, the efficacy of some neo-adjuvant regimens including 5-fluorouracil, cisplatin, and docetaxel have been less investigated. The present study evaluated the outcome and mid-term survival of patients with gastric cancer who undergoing this regimen.
In a randomized double-blinded controlled trial performed at the Firoozgar hospital in Tehran in 2011-12, 61 patients were randomly assigned to treatment (32 to neo-adjuvant chemotherapy with docetaxel, cisplatin and 5-fluorouracil (5-FU) before surgery and 27 to surgery alone). The present study tried to assess the efficacy of neoadjuvant chemotherapy regarding improvement of mid-term survival, complications, and R0 resection status.
The two groups were matched in terms of gender, mean age, cancer location, and TNM staging. However, R0 resection in the former group was 85.7%; while this indicator in the isolated surgery group was significantly lower (61.5%). Regarding WHO performance, no significant difference was observed across the two groups. Patients in neo-adjuvant chemotherapy group were followed for mean follow-up time 10.32 months and those who categorized in isolated surgery group were followed for mean follow-up time 10.88 months. Mid-term mortality rate in the two groups was 14.3% and 15.4%, respectively (p = 0.866). In this regard, 3-, 6-, and 9-month survival rate in neo-adjuvant chemotherapy group was 96.4%, 89.3%, and 85.7%, respectively. These survival rates in the surgery group were 92.3%, 88.5%, and 84.6%, respectively. Multivariable logistic regression analysis showed that among all study variables, only R0 resection status could predict mid-term mortality.
Neo-adjuvant chemotherapy and surgery compare to surgery alone more improve R0 resection status, but mid-term survival rate is similar in the two regiments. R0 resection status can effectively predict appropriate mid-term survival in undertreated patients.
近期研究已找到预防胃癌患者复发及提高其生存率的策略,包括术前新辅助治疗方法。然而,一些新辅助治疗方案,如5-氟尿嘧啶、顺铂和多西他赛的疗效研究较少。本研究评估了接受该方案治疗的胃癌患者的治疗结果及中期生存率。
在2011年至2012年于德黑兰菲罗兹加尔医院进行的一项随机双盲对照试验中,61例患者被随机分配接受治疗(32例接受术前多西他赛、顺铂和5-氟尿嘧啶(5-FU)新辅助化疗,27例仅接受手术)。本研究试图评估新辅助化疗在改善中期生存率、并发症及R0切除状态方面的疗效。
两组在性别、平均年龄、癌症位置及TNM分期方面相匹配。然而,前一组的R0切除率为85.7%;而单纯手术组的这一指标显著更低(61.5%)。关于世界卫生组织体能状态,两组间未观察到显著差异。新辅助化疗组患者的平均随访时间为10.32个月,单纯手术组患者的平均随访时间为10.88个月。两组的中期死亡率分别为14.3%和15.4%(p = 0.866)。在这方面,新辅助化疗组3个月、6个月和9个月的生存率分别为96.4%、89.3%和85.7%。手术组的这些生存率分别为92.3%、88.5%和84.6%。多变量逻辑回归分析表明,在所有研究变量中,只有R0切除状态可预测中期死亡率。
与单纯手术相比,新辅助化疗和手术更能提高R0切除状态,但两种治疗方案的中期生存率相似。R0切除状态可有效预测未充分治疗患者的中期生存情况。